67 results about "Coated drugs" patented technology

The invention relates to a process for producing a coated drug form or a drug form in the form of an active ingredient matrix, by processing a copolymer, an active pharmaceutical ingredient, a core if present and/or pharmaceutically customary excipients in a conventional manner by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading, spraying or compression to form a coated drug form and/or to form an active ingredient matrix, characterized in that a copolymer is used which is composed of 20 to 33% by weight methacrylic acid, 5 to 30% by weight methyl acrylate, 20 to 40% by weight ethyl acrylate and more than 10 to 30% by weight butyl methacrylate and, if desired, 0 to 10% by weight further vinylically copolymerizable monomers, with the proviso that the glass transition temperature of the copolymer in accordance with ISO 11357-2, section 3.3.3, is 55 to 70° C. The invention further relates to the drug form produced in accordance with the invention, to the copolymer, and to the use thereof.

A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

The invention relates to the field of synthesis of pharmaceutical chemistry and particularly relates to a specific method for ferroferric oxide, PDA-coated ferroferric oxide, pegylation and final drug-loading and various steps. A preparation method of pegylated polydopamine-coated drug-loaded magnetic nanoparticles specifically comprises the following steps: (1) synthesizing ferroferric oxide by adopting an alkaline coprecipitation method; (2) carrying out auto-polymerization on dopamine under an alkaline condition in the presence of the ferroferric oxide; (3) pegylating PDA-coated magnetic nanoparticles; and (4) carrying anti-cancer drug adriamycin to the magnetic nanoparticles by using hydrophobic interaction. The obtained composite nanodrug delivery system has the advantages of targeting delivery, high drug loading capacity and good biocompatibility.

An implantable medical device that can include an amorphous glass primer layer, an amorphous glass drug-containing layer and a nanoporous amorphous glass top-coat layer is disclosed.

There are provided an aqueous shellac coating agent comprising shellac, a basic amino acid and/or a basic phosphate as well as a production process therefor; a coated food and a coated drug that have been coated with such a coating agent; a glazing composition for oil-based confectionary which is in a liquid form and comprises an aqueous shellac solution (A) containing shellac, a basic amino acid and/or a basic based confectionary in which this glazing composition is applied, to oil-based confectionary to be glazed, thereby generating a glaze; and glazed oil-based confectionary produced using this process for glazing oil-based confectionary.

The invention belongs to the fields of biomedical polymer materials and particularly relates to a selenium or tellurium containing polymer as well as a preparation method and application of the selenium or tellurium containing polymer. The polymer is a selenium or tellurium containing amphiphilic block copolymer obtained by chemically bonding selenium or tellurium containing micromolecules and an amphiphilic block copolymer. The polymer can form micelles, microparticles, vesicles and microspheres under a proper condition and has the functions such as reductive response and coordination response. The particles can coat a drug to form a controlled-release drug conveying system, injection administration can be realized through various ways, and the coated drug can be released from the conveying system in a controlled-release way according to demands, so that the administration frequency is reduced, the treating effect is improved, and the toxic and side effects of the drug are reduced.

The invention discloses a device and a method for preparing pulsatile release microspheres. The device comprises three constant-flow pumps, coaxial nozzles, a frequency generator, a signal amplifier, an ultrasonic transducer, a collection container and a stirrer. The coaxial nozzles are three homocentric nozzles comprising an inner nozzle, a middle nozzle and an outer nozzle. The inner nozzle, the middle nozzle and the outer nozzle are connected respectively to the three constant-flow pumps by independent liquid delivery pipes and respectively convey a drug solution, a polymer solution and a stabilizing solution. The method comprises that through adjustment of flowing rates of the constant-flow pumps, jet flows produced by the coaxial nozzles; the ultrasonic transducer vibrates and resonates with the coaxial nozzles so that the jet flows are broken into uniform micro-droplets; the micro-droplets drop in the collection container with the stirrer; and particles prepared by the previous step are polymer solution-coated drugs and contact with the stabilizing solution so that a polymer is precipitated and is solidified into core-shell microspheres. Microsphere drug release is controlled by properties of a polymer and after a polymer shell is degraded, a drug is released intensively in a pulse way.

The invention discloses a synthesis method and use of a cholic acid-modified polyamino acid block copolymer. A hydrophilic chain of the block copolymer is polyethylene glycol, a hydrophobic chain of the block copolymer is polyamino acid, the tail end of the polyamino acid is modified through micromolecular cholic acid, the side chain of the polyamino acid is a lipoyl group, and lipoic acid and an amino group of hydrophobic polyamino acid undergo a reaction to produce an amido bond. Through crosslinking of a self-assembled nanometer micelle of the cholic acid-modified polyamino acid block copolymer, a stable crosslinked reduction-sensitive polymer nanometer micelle is obtained so that the nanometer micelle is not easily damaged in vitro and in blood and nanometer micelle-coated drug stability is guaranteed. When the nanometer micelle enters a cancer cell, the nanometer micelle can be fast decrosslinked and dissociated and the coated drug can be fast released and produce high efficiency treatment effects. The cholic acid-modified polyamino acid block copolymer solves the problems of early release of a drug in vivo, low carrying efficiency and a slow release rate in cells.

The invention discloses a nano cell membrane drug-loaded vesicle, a preparation method and application thereof. The preparation method is characterized in that through a physical extrusion technology,drug coating is carried out in the process of forming nanoscale cell membrane vesicles, no influence is generated on the activity of a coated drug, the in-vivo circulation time of the drug can be prolonged, the drug targeting ability is improved, and directional slow release of the drug is realized. The preparation method comprises the steps of cell membrane acquisition and cell membrane nano-vesicle preparation. Specific cell delivery of the drug targeting specific part can be realized, so that the drug fully plays a therapeutic role, and liver and kidney injury caused by one-time massive drug aggregation in the liver or kidney is prevented. Dynamic changes in a drug body can be tracked through probe wrapping.

The invention discloses a composition as well as a preparation method and a preparation thereof. The composition of the present invention includes nicotinamide mononucleotide, an ion exchange resin, acoating material, and a plasticizer. The preparation method comprises the following steps: preparing the drug-loaded resin particles, and coating the drug-loaded resin particles. The coated drug-loaded resin particles are mixed with other auxiliary materials to prepare corresponding dosage forms, such as oral suspension, tablets, capsules, granules, cream, ointment, facial masks and the like. Thecomposition is simple in production process, easy to amplify and produce, capable of effectively improving the stability of nicotinamide mononucleotide, accurate in dosage, lasting in effect and stable in curative effect.

The invention belongs to the field of medical drugs, and particularly relates to a manganese dioxide coated drug-loaded mesoporous titanium dioxide nanoparticle, and a preparation method and application thereof. The preparation method of the nanoparticles comprises the following steps: firstly, preparing mesoporous titanium dioxide by utilizing a solvothermal method and controlling the reaction temperature and time, then wrapping a manganese dioxide shell layer by utilizing a redox reaction of potassium permanganate, and finally loading a drug through electrostatic adsorption. The nanoparticlehas the advantages of low cost, good stability, good biocompatibility and the like, active oxygen and NO can be generated under action of in-vitro ultrasound, and combined application of sonodynamictherapy and NO therapy is achieved. Peroxynitrite with higher cytotoxicity can be further generated by the active oxygen and NO, and the tumor killing effect is enhanced.

The invention relates to methods for producing drugs having a stable profile for the release of active ingredients, said drugs exhibiting a controlled release characteristic as a result of the coating of vinyl (co)polymers. The inventive methods are characterised in that the coated drugs are conditioned in a fluidised bed coating appliance or a drum coating appliance for at least 10 minutes until a stable profile for the release of active ingredients is reached at a temperature of between 30 and 70° C. A humidity of between 5 and 30% is regulated during the conditioning process.

The invention provides a coating composition comprising zein, pectin and a plasticizer. The invention also provides a coated drug preparation and a preparation method thereof. The coating composition provided by the invention contains natural polymer zein and pectin, is good in stability and water resistance, and can effectively realize controlled release of a drug. The coated drug preparation provided by the invention adopts the coating composition for coating film coating, so that the controlled release of the drug at different time and different parts can be realized. The preparation method of the coated drug preparation provided by the invention is simple, is good in film forming property, and has a great potential for industrial application.

The invention discloses membrane-coated drug-loaded microspheres. Microcrystalline cellulose, organic calcium and bis (2-ethylhexyl) sodium sulfosuccinate are adopted as pore-forming agents of macroporous porous silicon, mesoporous or hollow or three-dimensional penetrating porous silicon dioxide is obtained after calcination, then acidizing treatment is conducted through hydrochloric acid, calcium in a silicon-calcium skeleton is dissolved and removed, and macroporous and three-dimensionally penetrated porous silica is obtained, the porous silicon framework and the surface of the porous silicon are very rough, pits and grooves are very rich, and loading and adhesion of drugs are facilitated. Besides, a drug-sustained-release parasite-expelling pet collar is prepared by using the membrane-coated drug-loaded microspheres so that the obtained pet collar has a good parasite-expelling effect, a long-acting sustained-release effect and a good quality guarantee effect. The product technology is mature, the production operation is simple and easy to understand, and the production cost is relatively reasonable.

There are provided an aqueous-shellac coating agent comprising shellac, a basic amino acid and/or a basic phosphate, as well as a production process therefor; a coated food and a coated drug that have been coated with such a coating agent; a glazing. composition for oil-based confectionary which is in a liquid form and comprises an aqueous shellac solution (A) containing shellac, a basic amino acid and/or a basic phosphate dissolved in water, a thickener (B), and/or a sugar (C); a process for glazing oil-based confectionary in which this glazing composition is applied to oil-based confectionary to be glazed, thereby generating a glaze; and glazed oil-based confectionary produced using this process for glazing oil based confectionary;

The invention relates to a preparation method of an amphiphilic biodegradable drug-loading micelle, which belongs to the technical field of drug preparations. The preparation method comprises the following steps: adopting amphiphilic biodegradable segmented copolymer as a loading material, dissolving the loading material and to-be-coated drug according to a ratio in an organic solvent to beservedas an oil phase solution, wherein the ratio of the to-be-coated drug to the loading material is 1: (0.25 to 10), and the mass volume concentration of the loading material in the organic solvent is 1 to 50 mg/ml; and preparing the amphiphilic biodegradable drug-loading micelle by adopting a dialysis method or a film hydration method. The preparation obtained by adopting the method provided byof theinvention has the advantages of stability in storage, safety in transportation and application, good dispersity of compound dispersion solution and the like; and the obtained amphiphilic biodegradable pesticide micelle is high in leaf remaining amount, good in dispersity, and haswide in application prospect in the fields of pesticide spraying, seed mixing and the like.

The invention relates to a preparation method of drug-loaded mesoporous calcium silicate modified PMMA bone cement as well as a product and application of the drug-loaded mesoporous calcium silicate modified PMMA bone cement. The preparation method comprises the steps of preparation of mesoporous calcium silicate, preparation of drug-loaded mesoporous calcium silicate, gelatin coating treatment and preparation of the modified PMMA bone cement. The gelatin-coated drug-loaded mesoporous calcium silicate is used as a drug carrier and a filler, so that the biocompatibility and osteogenic ability of the PMMA bone cement can be promoted, and the elastic modulus of the bone cement is reduced; the gelatin absorbs heat to accelerate the dissolution rate in water, the bioactive drug is crosslinked and fixed in mesopores, and under the protection of gelatin coating, the bioactive drug can be prevented from being inactivated due to polymerization heat release, so that the clinical application range of the bone cement is expanded.

The invention discloses a silicone-free high elasticity coated drug bottle plug and a manufacturing method, comprising a plug crown and a plug neck, wherein annular elastic ports are arranged on the lower end part of the plug crown, and a coating layer is arranged to cover the whole bottle plug. The height of one annular elastic port is equal to the thickness of a film partition side; the height of the second annular elastic port is the summation of the height of an annular elastic boss and the thickness of the film partition side; and the annular elastic boss is placed on the outer side of the plug crown. The method for manufacturing the silicone-free high elasticity coated drug bottle plug is as follows: 1) with adoption of a routine process, vulcanizing and forming integrated rubber sheets which are connected with a plurality of bottle plugs or the integrated rubber sheets which are connected with the plural bottle plugs with the annular elastic bosses via the film partition sides through a bottle plug mould; coating the whole integrated rubber sheets; and 3) annularly punching the integrated rubber sheets which are coated at punching points to obtain a finished product of the silicone-free high elasticity coated drug bottle plug. Compared with the existing bottle plug, the drug bottle plug produced by the invention is of better drug compatibility.

A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

The invention relates to a polydopamine-coated drug-loaded molybdenum disulfide nanosheet and preparation and application thereof. The method comprises the following steps: preparation of a molybdenum disulfide nanosheet, preparation of a molybdenum disulfide nanosheet with a polydopamine coating, preparation of a polyethylene glycol modified molybdenum disulfide nanosheet with the polydopamine coating, and preparation of the polydopamine-coated drug-loaded molybdenum disulfide nanosheet. The method is simple, has mild experimental condition, and is easy to operate, and the prepared polydopamine-coated drug-loaded molybdenum disulfide nanosheet not only can realize photoacoustic/CT bimodal imaging, but also can be used for photothermal therapy, chemotherapy and immune combined therapy of tumors, and has potential application value in the field of tumor diagnosis and treatment.

The invention discloses a polypeptide for inhibiting cell proliferation and inducing apoptosis and a preparation method and use thereof. The polypeptide disclosed by the invention comprises a polypeptide sequence 'SPHSG', namely YGRKKRRQRRR-GYLSKVRGISEVL, or another polypeptide sequence 'MRSP', which is similar to the polypeptide sequence in homology and function, namely YGRKKRRQRRR-DVKGYLSKVRGISEVL. An experimental basis is provided for application of the polypeptide in a coated balloon or a coated bracket. Compared with the traditional coated drug, the polypeptide does not have toxic or side effects and immunogenicity of chemical drugs as a small segment of Mfn2. The practicability is also superior to rapamycin. Therefore, the polypeptide has a wide application prospect and great clinical application value.

The invention discloses a new type coated drug bottle plug and a manufacturing method thereof, comprising a plug crown and a plug neck, wherein a sealing face between a bottle plug crown part and a plug port as well as a plug neck part are respectively provided with a coating layer. The method for manufacturing the coated drug bottle plug is as follows: 1) with adoption of a routine process, vulcanizing and forming integrated rubber sheets which are connected with plural bottle plugs via film partition sides through a bottle plug mould; 2) covering and sealing the plug crown face part of the single integrated rubber sheet or that of two integrated rubber sheets which are correspondingly clung and fixed with each other as a whole with shielding barriers; 3) coating the integrated rubber sheets which are covered and sealed as a whole; 4) removing the shielding barriers from the plug crown face parts; and 5) annularly punching the integrated rubber sheets which are coated at punching points to obtain a finished product of the new type coated drug bottle plug. Compared with the existing bottle plug, the drug bottle plug produced by the invention is of better drug compatibility.

The invention discloses a drug-loaded punctiform stent and a preparation method. The drug-loaded punctiform stent is mainly used for an interlayer after a subknee artery balloon dilatation molding operation. The drug-loaded punctiform stent comprises a short nickel-titanium alloy stent base body, the stent base body is of a self-expanding grid design structure, the surface of the stent base body is provided with uniform drug-loading micro-pits, and the surfaces of the uniform drug-loading micro-pits are coated with drug coatings. The preparation method comprises the steps that (1), a nickel-titanium alloy is processed into the stent base body, (2), the surface of the stent base body is treated; (3), corrosion treatment is carried out on the stent base body; (4), the corroded stent base body is cleaned; and (5), drug coating is carried out on the surface of the stent base body with the micro-pits. According to the drug-loaded punctiform stent, the shorter longitudinal length is combinedwith the opening design, so that the metal load on artery blood vessels is reduced to the greatest extent, the surface area in contact with the artery blood vessels is reduced, the drug-loaded punctiform stent is not prone to breaking and adapts to various blood vessel diameters, and coated drugs on the surface of the drug-loaded punctiform stent can be controlled to release; and the stent base body gives full play to supporting and drug treatment effects, and the occurrence rate of restenosis and target lesion blood supply reconstruction can be reduced.